Published 3 issues per year
ISSN Print: 0892-0915
ISSN Online: 2375-0014
A GABAergic Cortical Deficit Dominates Schizophrenia Pathophysiology
ABSTRACT
Several lines of evidence support the role of an epigenetic-induced GABAergic cortical dysfunction in schizophrenia psychopathology, which is probably dependent on an increase in the expression of DNA-methyltransferase-1 occurring selectively in GABAergic neurons. The key enzyme regulating GABA synthesis, termed glutamic acid decarboxylase 67 (GAD67) and the important neurodevelopmental protein called reelin are coexpressed in GABAergic neurons. Upon release, GABA and reelin bind to postsynaptic receptors located in dendrites, somata, or the axon initial segment of pyramidal neurons. Because GAD67 and reelin are downregulated in schizophrenia, it is suggested that schizophrenics may express GABAergic deficit-related alterations of pyramidal neuron function. A reduction of dendritic spines is a finding reported in the prefrontal cortex of schizophrenia patients. Because dendritic spines are innervated by glutamatergic axon terminals, very probably this reduction of dendritic spine expression is translated into a functional deficit of glutamatergic transmission. Plastic modifications of neuronal circuits are probably dependent on GABAergic transmitter tone, and it is likely that GABAergic dysfunction is at the root of synaptic plasticity deficits in schizophrenia. Thus, a possible avenue for the treatment of schizophrenia would be to address this GABAergic functional deficit using positive allosteric modulators of the action of GABA at GABAA receptors. Benzodiazepines (BZ) such as diazepam are effective in treating positive and negative symptoms of schizophrenia, but because they positively modulate GABAA receptors expressing α1 subunits, these BZs cause sedation and tolerance. In contrast, imidazenil, a full allosteric modulator of GABAA receptors expressing α5 subunits may reduce psychotic symptomatology without producing sedation. Hence, imidazenil should be appropriately studied as a prospective candidate for a pharmacological intervention in schizophrenia.
-
Guidotti Alessandro, Grayson Dennis R., A neurochemical basis for an epigenetic vision of psychiatric disorders (1994–2009), Pharmacological Research, 64, 4, 2011. Crossref
-
Hashimoto Kenji, Hattori Eiji, Neurotransmission, in Neurogenetics of Psychiatric Disorders, 2007. Crossref
-
Krystal John H., Moghaddam Bita, Contributions of Glutamate and GABA Systems to the Neurobiology and Treatment of Schizophrenia, in Schizophrenia, 2011. Crossref
-
McLeod Mark C., Scarr Elizabeth, Dean Brian, Effects of benzodiazepine treatment on cortical GABAA and muscarinic receptors: Studies in schizophrenia and rats, Psychiatry Research, 179, 2, 2010. Crossref
-
Geffen Yona, Nudelman Abraham, Gil-Ad Irit, Rephaeli Ada, Huang Mei, Savitsky Kinneret, Klapper Leah, Winkler Ilan, Meltzer Herbert Y., Weizman Abraham, BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia, European Neuropsychopharmacology, 19, 1, 2009. Crossref
-
Duncan Carlotta E., Webster Maree J., Rothmond Debora A., Bahn Sabine, Elashoff Michael, Shannon Weickert Cynthia, Prefrontal GABAA receptor α-subunit expression in normal postnatal human development and schizophrenia, Journal of Psychiatric Research, 44, 10, 2010. Crossref
-
Brown Alan S., The environment and susceptibility to schizophrenia, Progress in Neurobiology, 93, 1, 2011. Crossref
-
Li Chaoying, Carlier Paul R., Ren Hong, Kan Kelvin K.W., Hui Kwokmin, Wang Hong, Li Wenming, Li Zhiwang, Xiong Keming, Clement Ella Chow, Xue Hong, Liu Xiangou, Li Mingtao, Pang Yuanping, Han Yifan, Alkylene tether-length dependent γ-aminobutyric acid type A receptor competitive antagonism by tacrine dimers, Neuropharmacology, 52, 2, 2007. Crossref
-
Bob Petr, Palus Milan, Susta Marek, Glaslova Katerina, Sensitization, epileptic-like symptoms and local synchronization in patients with paranoid schizophrenia, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34, 1, 2010. Crossref
-
Cory‐Slechta Deborah A., Interactions of Lead Exposure and Stress: Implications for Cognitive Dysfunction, in Neurotoxicity and Developmental Disabilities, 30, 2005. Crossref
-
Fuster Joaquín M., Chemical Neurotransmission, in The Prefrontal Cortex, 2008. Crossref
-
Fusar-Poli Paolo, Pellegrini Francesco, Cortesi Mariachiara, Memantine as a neuroprotective agent in early phases of psychosis, Medical Hypotheses, 68, 2, 2007. Crossref
-
Dohi Akiko, Dillon Glenn H., Singh Meharvan, The Role of Progesterone and its Metabolites in Premenstrual Disorders of Affect, in Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders, 2008. Crossref
-
Jin Kunlin, Reelin and Stroke, in Reelin Glycoprotein, 2008. Crossref
-
Preda Adrian, Bota Robert, Harvey Philip, Neurocognitive Deficits, Negative Symptoms, and Insight in Schizophrenia, in Handbook of Schizophrenia Spectrum Disorders, Volume II, 2011. Crossref
-
Grayson Dennis R., Kundakovic Marija, Chen Ying, Dong Erbo, Guidotti Alessandro, Epigenetic Regulation of GABAergic Targets in Psychiatry, in Brain, Behavior and Epigenetics, 2011. Crossref
-
Lucchese Guglielmo, Flöel Agnes, Stahl Benjamin, A Peptide Link Between Human Cytomegalovirus Infection, Neuronal Migration, and Psychosis, Frontiers in Psychiatry, 11, 2020. Crossref
-
Conti Elisa, Andreoni Simona, Tomaselli Davide, Storti Benedetta, Brovelli Francesco, Acampora Roberto, Da Re Fulvio, Appollonio Ildebrando, Ferrarese Carlo, Tremolizzo Lucio, Serum DBI and biomarkers of neuroinflammation in Alzheimer’s disease and delirium, Neurological Sciences, 42, 3, 2021. Crossref
-
Zhang Tie-Yuan, Meaney Michael J., Epigenetics and the Environmental Regulation of the Genome and Its Function, Annual Review of Psychology, 61, 1, 2010. Crossref
-
Bitanihirwe BKY, Lim MP, Kelley JF, Kaneko T, Woo TUW, Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia, BMC Psychiatry, 9, 1, 2009. Crossref
-
Bob Petr, Touskova Tereza Petraskova, Pec Ondrej, Raboch Jiri, Boutros Nash, Lysaker Paul, Psychosocial Stress, Epileptic-Like Symptoms and Psychotic Experiences, Frontiers in Psychology, 13, 2022. Crossref
-
Kehne John H., Maynard George D., GABA and Schizophrenia, in Targets and Emerging Therapies for Schizophrenia, 2012. Crossref